Dr. John Cush RheumNow
3 years 3 months ago
Danger with Hydroxychloroquine Nonadherence in SLE
A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.
https://t.co/RFPQZXQMeI https://t.co/eu1rhVyV18
The AURORA 2 study evaluated the long-term safety and efficacy of voclosporin lupus nephritis patients and, after three years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.
A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
Dr. John Cush RheumNow
3 years 3 months ago
SLE and Pregnancy Outcomes
Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease.
https://t.co/BeCQYTq928 https://t.co/M6oILWfah1
Dr. John Cush RheumNow
3 years 3 months ago
EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis
The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest.
https://t.co/KYLBU3E0k6 https://t.co/oHgqEX8Gr6
Dr. John Cush RheumNow
3 years 3 months ago
Belgian study of 312 PsA & 213 SpA pts showed that most had normal spinal Xrays (87.5% PsA, 92% SpA). SpA pts had higher mSASSS than PsA (p<0.05). More Cx (73%) than Lumbar (33%) in PsA; SpA, CX (64%) & LS (71%) evenly distributed https://t.co/Z8JRRuxmWZ https://t.co/8uMiAsk7aA
Dr. John Cush RheumNow
3 years 3 months ago
Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/j4Cd42akx6 https://t.co/rQ6vZRw34A
Dr. John Cush RheumNow
3 years 3 months ago
Post hoc analysis 2 phase III RCTs of abatacept (Sc & IV) in 409 polyarticular JIA pcJIA. ABA was effective (by JIA-ACR and JADAS27 responses) & well tolerated, regardless of concomitant or prior MTX use. https://t.co/cTn52V5Fuu https://t.co/CUqin00LZh
U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. Immune complexes (ICs) composed of RNA-containing autoantigens and autoantibodies are suspected to be involved in the pathogenesis of some systemic autoimmune diseases.
Dr. John Cush RheumNow
3 years 3 months ago
Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/HZYR7FA7i1 https://t.co/jvlot0OIw4
A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.
Dr. John Cush RheumNow
3 years 3 months ago
Nonprofit Allen Institute for Immunology will partner with researchers from Eli Lilly to investigate and profile disease state diversity and biomarkers for drug response in atopic dermatitis and rheumatoid arthritis https://t.co/nRbdWdFx7C https://t.co/rlngbtxgUo
In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.
Dr. John Cush RheumNow
3 years 3 months ago
Research from 12 states with medical cannabis laws looked at 583 820 adults w/ chronic noncancer pain. Data over 3 yres shows < 0.05% change in the use of opioid prescriptions, nonopioid prescriptions, pain meds, or chr pain procedures https://t.co/ArbP4xe4dH https://t.co/MPRBZNIIoS
Dr. John Cush RheumNow
3 years 3 months ago
Top 10-selling drugs accts for 22% of Medicare part D spending ($47.7/$215.7 billion)
Eliquis $12.6 Billion
Trulicity $4.7 B
Januvia $4.1B
Jardiance $3.7B
Lantus $2.8B
Ozempic $2.6B
Revlimid $5.9B
Xarelto $5.2B
Imbruvica $3.2B
Humira $2.9B
https://t.co/5rvLldNLF0 https://t.co/OOt8he8Ig4

